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Hereditary non-polyposis colorectal cancer (HNPCC orLynch syndrome) is an autosomal dominant predisposi-tion for early onset colorectal cancer and other tumours.
The mean age at diagnosis of colorectal cancer is about 44
years.1 At least five genes have been associated with errors in
DNA mismatch repair, the genetic basis of HNPCC. A large
proportion of HNPCC families (50%–60%) harbour changes in
one of two genes, hMSH2 and hMLH1.2 Genetic testing for
HNPCC has been possible since 1993/4.3 In HNPCC, two
important goals of genetic testing are (1) to identify those
with a high risk (mutation positive) to promote preventive
strategies and reduce morbidity and mortality; and (2) to
reduce unnecessary worry among those with a low risk of
cancer (mutation negative).4 In mutation positive families,
predictive testing can determine who is a carrier of a known
mutation in the family, and who is not. Carriers of an HNPCC
mutation are estimated to have a lifetime risk of developing
colorectal cancer of about 80%.5 These carriers are advised to
adhere to a lifelong screening programme for early detection
of colorectal polyps. The screening programme currently
includes a colonoscopy every one to two years,1 6 7 and should
be initiated when the patient is between the ages of 20 and
25.1 Regular screening reduces substantially themorbidity and
mortality from colorectal cancer.8 Those found not to be carri-
ers of the mutation that runs in their family, “HNPCC
mutation negative family members”, are discharged from this
burdensome, lifelong surveillance programme. Their risk and
that of their children of developing colorectal cancer reverts to
that of the general population (5%). In The Netherlands, there
is currently no colorectal surveillance programme for the gen-
eral population aged 50 years and over, as is the case in some
other countries.
Aktan-Collan et al 9 reported that HNPCC mutation negative
subjects were less anxious than mutation positive subjects
immediately after disclosure of their predictive genetic test
results, but these differences were no longer present after one
and 12 months of follow up. However, neither this nor other
studies have investigated the impact of negative test results on
attitudes toward discharge from colon screening or actual sur-
veillance behaviour in HNPCC families.10 Although it is gener-
ally assumed that discharge from screening will be experi-
enced as a relief, this assumption has yet to be confirmed
empirically. A recent study of another hereditary colorectal
cancer syndrome, familial adenomatous polyposis (FAP),
found that 42% of those who had received a negative
predictive genetic test result intended to (continue to)
undergo colon screening in the future despite the fact that it
was no longer necessary to do so.11 Whether such continued
vigilance is also prevalent among those found to be
non-carriers of an HNPCC mutation is unknown.
METHODS
As part of a larger, retrospective study of the experience of
those counselled for the familial occurrence of colorectal can-
cer, we investigated the psychosocial impact of receiving a
negative DNA test result. The study comprised all those coun-
selled for the familial occurrence of colorectal cancer at three
family cancer clinics in Amsterdam during the period
1986–98. Both asymptomatic subjects and those ever treated
for cancer were invited to participate in the study. The study
was approved by the institutional ethics committees of the
three participating hospitals.
Of the 214 counsellees eligible for the overall study, 178
returned a completed questionnaire (83%). Among the 178
respondents, 25 were established to be non-carriers of the
pathogenic mutation detected in their families (response
within non-carriers 83%), and 31 were found to be carriers of
a pathogenic HNPCC mutation (response within carriers
84%). The remaining 122 counsellees received a risk estima-
tion and screening advice based on their family history only,
either because DNA testing was not available or performed at
the time they were counselled (n=108) or because the DNA
test yielded inconclusive results (n=14). In this letter, we
report data on the HNPCC mutation negative and positive
counsellees.
As part of a self-report questionnaire assessing a wide range
of psychosocial issues, three questions adapted from Lerman et
al12 were posed about the prevalence of cancer worries: “Dur-
ing the past year, how frequently did you worry about the risk
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Abbreviations: FAP, familial adenomatous polyposis; HNPCC,
hereditary non-polyposis colorectal cancer
Key points
• The purpose of the study was to investigate the experi-
ence of discharge from colonoscopy of mutation nega-
tive HNPCC family members.
• As part of a larger, retrospective study, 25 established
non-carriers and 31 carriers of a pathogenic HNPCC
mutation completed a questionnaire.
• None of the non-carriers reported being often worried
about their own cancer risk, compared to 19% of the
carriers. Only 3% of the non-carriers and 4% of the car-
riers reported that concerns about cancer had a signifi-
cant impact on their daily functioning during the past
year. Of the non-carriers, 82% were pleased that they
no longer needed to undergo screening. However, 32%
were concerned with their discharge from screening,
suggesting conflicting positive and negative feelings
among some subjects.
• Most non-carriers are pleased that colonoscopies are
no longer necessary, but about one third have some
concerns about stopping surveillance. These concerns
should be addressed during the final consultation with
the geneticist or gastroenterologist.
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of developing cancer”, “During the past year, how frequently
did your worries about cancer have an impact on your daily
functioning?”, and “During the past year, how frequently did
you worry about the risk of cancer in members of your
family”. Response categories included “almost never”, “some-
times”, “often”, and “almost always”. Those found to be
HNPCC mutation negative were also asked to answer the fol-
lowing questions: “When were you told that colonoscopies
were no longer necessary?”, “Did you undergo colon screening
before this date?”, “Did you undergo colon screening after this
date?”, “Are you pleased that colon screening is no longer
necessary?”, and “Are you concerned about having been
discharged from colon screening?”. The questionnaire was
sent, on average, four years (SD 2 years, median 3 years) after
they had received their final counselling session during which,
if tested, personal DNA test results were discussed.
RESULTS
The HNPCC mutation negative counsellees comprised 12 men
and 13 women with a mean age of 48 years at the time of
completion of the questionnaire (SD 9 years, range 29–63
years). Of these 25 counsellees, three had been treated for
benign polyps in the past; the remaining 22 had no personal
history of polyps or cancer. The mean age of 31 mutation posi-
tive counsellees was 42 years (SD 10 years, range 26–58 years).
Of the 18 male and 13 female carriers, 10 had been treated for
polyps or colorectal cancer in the past.
As shown in table 1, none of the non-carriers reported being
“often”, or “almost always” worried about their own cancer
risk, compared to 19% of the carriers (p=0.06). Only a small
percentage of the non-carriers and carriers (3% and 4%,
respectively) reported that concerns about cancer had had a
significant impact on their daily functioning during the past
year. Relatively few respondents reported being frequently
concerned about the risk of cancer for other family members
(12% and 13% for the non-carriers and carriers, respectively).
Of the 25 non-carriers, one had never had a colonoscopy, 10
had undergone one colonoscopy, six had had two colonoscop-
ies, and eight had had three or more colonoscopies. Of the 22
counsellees who responded to the questions about discharge,
most (82%) were pleased with the fact that they no longer
needed to undergo screening. However, of the 22 respondents,
seven (32%) reported that they were concerned with their
discharge from screening. Of these seven, three had also
reported that they were pleased that the screening was no
longer required, suggesting the presence of conflicting
feelings. Only one counsellee reported having undergone a
colonoscopy about one year after having been discharged from
the surveillance programme. This woman had been under
surveillance since 1975 and had no personal history of polyps
or cancer. Her motives for undergoing colonoscopy after hav-
ing been discharged were unclear.
DISCUSSION
These results suggest that, although worries about developing
colorectal cancer are infrequent and most non-carriers are
pleased that colonoscopies are no longer necessary, about one-
third of non-carriers have some concerns about stopping sur-
veillance. The reasons for these concerns are unclear. It might
be that, as in the study by Michie et al,11 some people doubt the
accuracy of the genetic test results. This issue should be inves-
tigated in future studies, preferably with larger samples and
using a prospective design. Although it is generally accepted
that discharge from surveillance is one of the greatest benefits
of genetic counselling for colorectal cancer, clinical geneticists
and gastroenterologists need to be aware of the fact that, for
some HNPCC mutation negative family members, concerns
remain. During the final consultation with the geneticist or
gastroenterologist, these concerns should be addressed and,
depending on local guidelines, participation in a general
population surveillance programme might be recommended.
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Table 1 Cancer worries during the past year:
percentage of non-carriers (n=25) and carriers (n=31)
Almost
never (%)
Sometimes
(%)
Often/almost
always (%)
Worries about own cancer risk:
Non-carriers 68 32 0
Carriers 52 29 19
Worries had impact on daily functioning:
Non-carriers 88 8 4
Carriers 87 10 3
Worries about cancer risk in relatives:
Non-carriers 32 56 12
Carriers 43 43 13
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